Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review

por Persson, Frederik, Lindhardt, Morten, Rossing, Peter, Parving, Hans-Henrik
Publicado 2016

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With N...

por Lajer, Maria, Jorsal, Anders, Tarnow, Lise, Parving, Hans-Henrik, Rossing, Peter
Publicado 2010

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

por Andersen, Sten, Mischak, Harald, Zürbig, Petra, Parving, Hans-Henrik, Rossing, Peter
Publicado 2010

Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes

por Joergensen, Christel, Hovind, Peter, Schmedes, Anne, Parving, Hans-Henrik, Rossing, Peter
Publicado 2011

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study

por Hovind, Peter, Rossing, Peter, Tarnow, Lise, Johnson, Richard J., Parving, Hans-Henrik
Publicado 2009

Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study

por Gæde, Peter, Oellgaard, Jens, Kruuse, Christina, Rossing, Peter, Parving, Hans-Henrik, Pedersen, Oluf
Publicado 2019

Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients

por Nielsen, Stine Elkjaer, Sugaya, Takeshi, Hovind, Peter, Baba, Tsuneharu, Parving, Hans-Henrik, Rossing, Peter
Publicado 2010

Vitamin D Levels and Mortality in Type 2 Diabetes

por Joergensen, Christel, Gall, Mari-Anne, Schmedes, Anne, Tarnow, Lise, Parving, Hans-Henrik, Rossing, Peter
Publicado 2010

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2...

por Oellgaard, Jens, Gæde, Peter, Rossing, Peter, Rørth, Rasmus, Køber, Lars, Parving, Hans-Henrik, Pedersen, Oluf
Publicado 2018

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy

por Persson, Frederik, Lewis, Julia B., Lewis, Edmund J., Rossing, Peter, Hollenberg, Norman K., Parving, Hans-Henrik
Publicado 2010

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

por Gæde, Peter, Oellgaard, Jens, Carstensen, Bendix, Rossing, Peter, Lund-Andersen, Henrik, Parving, Hans-Henrik, Pedersen, Oluf
Publicado 2016

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception coh...

por Ferreira, Isabel, Hovind, Peter, Schalkwijk, Casper G., Parving, Hans-Henrik, Stehouwer, Coen D. A., Rossing, Peter
Publicado 2017

Osteoprotegerin and Mortality in Type 2 Diabetic Patients

por Reinhard, Henrik, Lajer, Maria, Gall, Mari-Anne, Tarnow, Lise, Parving, Hans-Henrik, Rasmussen, Lars M., Rossing, Peter
Publicado 2010

A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study

por Gæde, Joachim, Oellgaard, Jens, Ibsen, Rikke, Gæde, Peter, Nørtoft, Emil, Parving, Hans-Henrik, Kjellberg, Jakob, Pedersen, Oluf
Publicado 2018

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials

por Idzerda, Nienke M A, Pena, Michelle J, Parving, Hans-Henrik, de Zeeuw, Dick, Heerspink, Hiddo J L
Publicado 2019

The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes

por Dendooven, Amélie, Nguyen, Tri Q, Brosens, Lodewijk, Li, Dongxia, Tarnow, Lise, Parving, Hans-Henrik, Rossing, Peter, Goldschmeding, Roel
Publicado 2011

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

por Koomen, Jeroen V., Stevens, Jasper, Mostafa, Nael M., Parving, Hans‐Henrik, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Publicado 2018

Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes: Results and projections from the Steno-2 study

por Gæde, Peter, Valentine, William J., Palmer, Andrew J., Tucker, Daniel M.D., Lammert, Morten, Parving, Hans-Henrik, Pedersen, Oluf
Publicado 2008

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial

por Lund, Søren S, Tarnow, Lise, Frandsen, Merete, Nielsen, Bente B, Hansen, Birgitte V, Pedersen, Oluf, Parving, Hans-Henrik, Vaag, Allan A
Publicado 2009

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analy...

por Hellemons, Merel E., Persson, Frederik, Bakker, Stephan J.L., Rossing, Peter, Parving, Hans-Henrik, De Zeeuw, Dick, Lambers Heerspink, Hiddo J.
Publicado 2011